Oncopeptides AB

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.685 ^SEK	+5.50%		+5.92%	-64.95%

Jul. 02	An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (OM:ONCO) from Industrifonden for SEK 22.4 million.	CI
Jun. 27	Oncopeptides AB Selects First Candidate Drug from Its Spike Platform	CI

Oncopeptides AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 30, 2024 at 02:00 am EDT

Oncopeptides AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 5.07 million compared to SEK 1.12 million a year ago. Net loss was SEK 67.71 million compared to SEK 71.03 million a year ago.

Latest news about Oncopeptides AB

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (OM:ONCO) from Industrifonden for SEK 22.4 million.	Jul. 01	CI
Oncopeptides AB Selects First Candidate Drug from Its Spike Platform	Jun. 27	CI
Transcript : Oncopeptides AB - Special Call	Jun. 26
Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank	May. 30	MT
Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024	May. 30
Oncopeptides AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30	CI
Oncopeptides’ Multiple Myeloma Drug Set for First Patient Use in Spain	May. 27	MT
Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	May. 16	CI
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15	CI
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13	MT
Transcript : Oncopeptides AB, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
FDA Officially Withdraws Approval of Oncopeptides Pepaxto	Feb. 23	DJ
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	Feb. 23	MT
Spanish Authority Gives Positive Recommendation for Pricing of Oncopeptides' Blood Cancer Drug	Feb. 23	MT
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	Feb. 23	CI
Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037	Feb. 15	MT
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	Dec. 15	CI
Oncopeptides' New CFO Takes Office	Nov. 13	MT
Oncopeptides Selects to Present Additional Data from Ocean Study	Nov. 13	CI
Oncopeptides AB Appoints Henrik Bergentoft as Chief Financial Officer	Nov. 13	CI

Chart Oncopeptides AB

Duration

Period

More charts

Company Profile

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Companyâs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Oncopeptides AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.685 SEK

Average target price

6.1 SEK

Spread / Average Target

+127.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOPEPTIDES AB	-64.95%	52.23M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	127B
REGENERON PHARMACEUTICALS, INC.	+25.25%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.51%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-15.63%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs